ANI Pharmaceuticals announced that the Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Oxycodone HCl Oral Solution.
Oxycodone HCl is an opioid agonist indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. Oxycodone HCl is a pure agonist opioid that has multiple actions qualitatively similar to those of morphine. The most prominent of these involves the central nervous system and organs composed of smooth muscle.
Oxycodone HCl Oral Solution will be available in a 5mg/5mL strength. ANI is expected to begin shipment shortly.
For more information call (800) 434-1121 or visit ANIpharmaceuticals.com.